Clinical Trial

Namodenoson Treatment of Advanced Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 31, 2025 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-26; most recent amendment 2025-01-29.
Status change: Not Yet Recruiting → Recruiting 2025-01-29
Trial Details
NCT Number NCT06387342
Lead Sponsor Can-Fite BioPharma
Conditions Pancreatic Adenocarcinoma, Pancreatic Cancer
Enrollment 20 participants
Start Date 2024-11-10
Primary Completion 2026-07-15 (estimated)
Study Completion 2026-12-15 (estimated)
Updated on ClinicalTrials.gov 2025-01-31